Developing new technologies to discover cancer treatment targets using CRISPR-Cas9
Development of microfluidic enabled CRISPR-Cas9 functional genetic screening technologies for target discovery in cancer immunotherapy
['FUNDING_R01'] · NORTHWESTERN UNIVERSITY · NIH-11098557
This study is exploring how to use a special gene-editing tool to find out which genes help cancer cells survive, with the hope of discovering new ways to boost the immune system to fight cancer better.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NORTHWESTERN UNIVERSITY (nih funded) |
| Locations | 1 site (Chicago, UNITED STATES) |
| Trial ID | NIH-11098557 on ClinicalTrials.gov |
What this research studies
This research focuses on using advanced CRISPR-Cas9 technology to conduct large-scale genetic screenings that identify key genetic factors influencing cancer cell survival. By modifying the genetic makeup of millions of cells, the study aims to uncover new targets for cancer immunotherapy. The approach utilizes a novel microfluidic system that allows for rapid sorting of live cells, ensuring high viability during the screening process. This could lead to significant advancements in understanding how to effectively activate the immune system against cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with various types of cancer who may benefit from innovative immunotherapy treatments.
Not a fit: Patients with non-cancerous conditions or those who do not respond to immunotherapy may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the discovery of new therapeutic targets that enhance the effectiveness of cancer immunotherapy.
How similar studies have performed: Other research has shown promising results using CRISPR-Cas9 technology for genetic screening, indicating that this approach has potential for success.
Where this research is happening
Chicago, UNITED STATES
- NORTHWESTERN UNIVERSITY — Chicago, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KELLEY, SHANA O — NORTHWESTERN UNIVERSITY
- Study coordinator: KELLEY, SHANA O
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anti-cancer therapy, anticancer immunotherapy